LABORATORY CORP OF AMERICA HOLDINGS·4

Feb 9, 12:02 PM ET

Kirchgraber Paul R 4

4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Feb 9, 2023

Insider Transaction Report

Form 4
Period: 2023-02-07
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
  • Award

    Non-qualified Stock Options

    2023-02-07+5,0005,000 total
    Exercise: $247.24From: 2024-02-07Exp: 2033-02-06Common Stock (5,000 underlying)
  • Award

    Restricted Stock Unit

    2023-02-07+1,5903,484 total
    Common Stock (1,590 underlying)
Footnotes (5)
  • [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
  • [F2]The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024.
  • [F3]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
  • [F4]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
  • [F5]The option vests in three equal annual installments beginning on the date reflected in this column.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT